**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 79388

**Manuscript Type:** MINIREVIEWS

**Recent advances in the management of autoimmune pancreatitis in the era of artificial intelligence**

Mack S *et al*. Advances in AIP management

Sahar Mack, Yves Flattet, Philippe Bichard, Jean Louis Frossard

**Sahar Mack, Yves Flattet, Philippe Bichard, Jean Louis Frossard,** Division of Gastroenterology, Department of Medical Specialties, University Hospital of Geneva, Geneva 1205, Switzerland

**Author contributions:** Mack S and Flattet Y performed research and wrote the paper; Bichard P and Frossard JL contributed critical revision of the manuscript for important intellectual content.

**Corresponding author: Jean Louis Frossard, MD, Associate Professor,** Division of Gastroenterology, Department of Medical Specialties, University Hospital of Geneva, Rue Gabrielle-Perret-Gentil 4, Geneva 1205, Switzerland. jean-louis.frossard@hcuge.ch

**Received:** August 18, 2022

**Revised:** October 31, 2022

**Accepted:** November 16, 2022

**Published online:**

**Abstract**

Autoimmune pancreatitis (AIP) is a type of immune-mediated pancreatitis subdivided into two subtypes, type 1 and type 2 AIP. Furthermore, type 1 AIP is considered to be the pancreatic manifestation of the immunoglobulin G4 (IgG4)-related disease. Nowadays, AIP is increasingly researched and recognized, although its diagnosis represents a challenge for several reasons: False positive ultrasound-guided cytological samples for a neoplastic process, difficult to interpret levels of IgG4, the absence of biological markers to diagnose type 2 AIP, and the challenging clinical identification of atypical forms. Furthermore, 60% and 78% of type 1 and type 2 AIP, respectively, are retrospectively diagnosed on surgical specimens of resected pancreas for suspected cancer. As distinguishing AIP from pancreatic ductal adenocarcinoma can be challenging, obtaining a definitive diagnosis can therefore prove difficult, since endoscopic ultrasound fine-needle aspiration or biopsy of the pancreas are suboptimal. This paper focuses on recent innovations in the management of AIP with regard to the use of artificial intelligence, new serum markers, and new therapeutic approaches, while it also outlines the current management recommendations. A better knowledge of AIP can reduce the recourse to surgery and avoid its overuse, although such an approach requires close collaboration between gastroenterologists, surgeons and radiologists. Better knowledge on AIP and IgG4-related disease remains necessary to diagnose and manage patients.

**Key Words:** Autoimmune pancreatitis; Pancreatic ductal adenocarcinoma; Immunoglobulin G4-related disease; Prednisone; Rituximab; Artificial intelligence; Plasmablasts

Mack S, Flattet Y, Bichard P, Frossard JL. Recent advances in the management of autoimmune pancreatitis in the era of artificial intelligence. *World J Gastroenterol* 2022; In press

**Core Tip:** The diagnosis of autoimmune pancreatitis (AIP) is challenging. Indeed, 60% and 78% of type 1 and type 2 AIP, respectively, are retrospectively evaluated on surgical specimens of resected pancreas for suspected cancer. Obtaining a definitive diagnosis can thus prove difficult, since endoscopic ultrasound fine-needle aspiration or biopsy of the pancreas are suboptimal. This paper focuses on recent innovations in the management of AIP using artificial intelligence, new serum markers, and new therapeutic approaches and outlines the current recommendations. Improved knowledge of AIP can reduce the recourse to surgery, although this requires collaboration between gastroenterologists, surgeons and radiologists.

**INTRODUCTION**

Autoimmune pancreatitis (AIP) is a type of chronic fibro-inflammatory response in immune-mediated pancreatitis[1,2]. Histological examination reveals diffuse lymphoplasmacytic infiltration associated with extensive storiform fibrosis, acinar atrophy, and obliterative venulitis[2,3]. Radiological imaging shows ductal stenosis and an enlarged pancreas or pancreatic mass resembling pancreatic ductal adenocarcinoma (PDAC)[3]. The distinction between these two entities is sometimes difficult and has clear therapeutic implications. Indeed, AIP has a good response to steroids, which constitutes an important diagnostic criterion[4,5].

In the last decade, the prevalence of AIP has increased worldwide due to the better description and recognition of the disease[6-8]. In the majority of the studies conducted in Asian countries, its prevalence more than doubled between 2011 and 2016. In Japan, for example, the prevalence was estimated at 10.1 per 100000 inhabitants in 2016 with an annual incidence of 3.1 per 100000 inhabitants[7]. The prevalence in Europe seems to be less than 1 per 100000 inhabitants (0.29/100000), or 9% of patients with non-alcoholic acute pancreatitis[8], although these numbers are most certainly underestimated due to the lack of diagnoses and the occurrence of paucisymptomatic cases that do not require treatment[8].

Two AIP subtypes, AIP-1 and AIP-2, present different clinical profiles such as mean age at disease onset, male/female ratio, geographical distribution, as well as histological and immunological features (Table 1)[9,10]. AIP-1, the most prevalent type in Asia, is a systemic disease with the possible involvement of other organs, higher immunoglobulin G4 (IgG4) in blood, IgG4 positive infiltrates, as well as increased autoantibody levels in blood. AIP-1 primarily affects men aged over 50 years and is currently considered the pancreatic manifestation of the IgG4-related disease[11]. AIP-2 corresponds to the idiopathic duct-centric pancreatitis, which can be identified by pathognomonic histological features known as granulocyte epithelial lesions[9,12]. This subgroup is more common in Europe and affects younger patients with an equivalent male/female ratio. AIP-2 often occurs with isolated cases of pancreatitis without other organ involvement, although it is associated with chronic inflammatory bowel disease in 20%-30% of cases[6,13]. The physiopathological mechanisms of AIP are poorly understood and multiple immunological pathways have been proposed. The aim of this paper is not to describe these different mechanisms.

**Establishing a diagnosis**

Several diagnostic criteria have been proposed for AIP based on its clinical, biological, radiological and histological presentation in addition to treatment response: Diagnostic criteria of the Japanese (2002, 2006)[14], Korean (2007), Asian (2008) and Italian Societies of Gastroenterology (2003, 2009), as well as the Mannheim (2009) and HISORt criteria (2009)[15]. With the improved detection of AIP-2 and IgG4-related disease, a group of international experts published new reference criteria known as the International Consensus Diagnostic Criteria (ICDC) in 2011 with five main diagnostic criteria categorized according to two levels of evidence (Tables 2 and 3)[10]. New Japanese diagnostic criteria (JPS2011 followed by JPS2018) were subsequently published[16,17]. Unlike the ICDC criteria, the JPS2011 criteria provided the following clarifications: (1) Differentiation between diffuse, segmental and focal types in the classification; (2) Blood IgG4 used as the only biological marker; (3) Sclerosing cholangitis, sclerosing sialadenitis and retroperitoneal fibrosis classified as other organ involvement; (4) No level of evidence given for other organ involvement or serological criteria (IgG4); and (5) The optional use of steroids only after excluding pancreatic cancer by fine-needle aspiration (FNA)[16]. In 2018, the JPS2018 added two new factors to its diagnostic criteria: The use of magnetic resonance imaging (MRI) for radiological diagnosis, primarily using magnetic resonance cholangiopancreatography, and the use of endoscopic ultrasound (EUS)-FNA in order to exclude a neoplastic process by histology[17].

The main limitation of this diagnostic algorithm concerns AIP-2 patients with normal IgG4 levels and disease limited to the pancreas[18]. Indeed, 50% of AIP-1 patients present with other organ involvement[19], which facilitates the diagnosis. If specific clinical, morphological, or biological evidence confirms the AIP diagnosis, no further investigation is necessary. Nevertheless, in the presence of a focal mass or diffuse pancreatic enlargement without associated autoimmune disease or specific biological and morphological features, a biopsy is necessary for histological analysis. The effectiveness and feasibility of obtaining pancreatic samples by EUS-FNA or biopsy (EUS-FNB) are still the subject of debate. Indeed, the primary aim of EUS-FNA and EUS-FNB is to collect pancreatic tissue so as to exclude a malignant process and thus contribute to the AIP diagnosis. The ICDC therefore recommends the use of biopsy tissue (trucut biopsy). However, given that this procedure is not feasible in all healthcare establishments, it is not compulsory in the diagnostic algorithm, although it is an important diagnostic criteria of the JPS2018 classification[17]. In the last decade, the proportion of pancreatic samples obtained by EUS has significantly increased from 48% in 2007 to 86% in 2016 in Japan[7]. Several studies nevertheless report the difficulty in diagnosing AIP with EUS-FNA (sensitivity of 43%-60%) and obtaining a sufficient amount of fibrotic tissue[11-16], which explains the shift toward EUS-FNB[20,21]. A Japanese study on 44 AIP patients obtained an adequate histological sample in 93% of cases, leading to a confirmed diagnosis of AIP in 43% of cases, a diagnosis of idiopathic chronic pancreatitis (CP) in 50% of cases, and no false positives for pancreatic cancer[22].

***Laboratory tests***

The serological diagnostic criteria corresponds to IgG4 levels at the upper limit of normal between 135 and 140 mg/dL[23]. It is generally accepted that IgG4 levels twice the normal limit are a valid criteria for AIP, although this can also occur in 10% of PDAC. Moreover, elevated IgG4 levels that are more than twice the normal value are associated with recurrence and exocrine pancreatic insufficiency in IgG4-related disease[24]. Nonetheless, some AIP-1 cases do not present elevated blood IgG4 or IgG4-positive cells on histology[25].

The efficacy of monoclonal anti-CD20 antibodies in AIP highlights the possible involvement of B cells in the pathogenesis of this disease[26,27]. Two types of B cells have been investigated in IgG4-related disease: Regulatory B cells and plasmablasts. Derived from the B cell lineage, plasmablasts are characterized as CD27+CD38+, which situates them between B cells and plasmocytes. Diagnostic tools such as the quantification of circulating plasmablasts in serum have already been shown to contribute to the diagnosis of AIP in patients with autoimmune disease[10]. In a retrospective study on 37 patients with IgG4-related disease, all patients showed high levels of plasmablasts, while only 64% had high IgG4 serum[28].

***Imaging***

When investigating pancreatic lesions, several types of imaging are necessary, as no single imaging technique can provide a definitive diagnosis of AIP. The most typical feature is a global enlargement of the pancreatic gland associated with the loss of lobulations, giving it a sausage-like appearance[29]. The capsule-like rim sign, which can also be seen with other procedures, is a relatively distinctive feature of AIP in computed tomography (CT). This sign is defined by a band-like structure around all or part of the pancreas. It is characterized by a lower absorption than the pancreatic parenchyma of the lesion during the pancreatic parenchymal phase and shows a delayed enhancement pattern with dynamic CT. Other elements have been described such as decreased peripheral enhancement causing a peripheral halo or ring, involution of the pancreatic tail, enhancement of the thickened bile duct wall resembling a cocoon, stenosis of the Wirsung duct without upstream dilation, and focal hyperdense pseudotumors. MRI shows a loss of T1 signal intensity and the T2 hyperintensity of the parenchyma correlated with an inflammation of the gland. In terms of ducts, stenosis of the Wirsung duct without upstream dilation can be observed, even in the focal pseudotumors[29]. A capsule-like rim reflecting the strong fibrosis of the peripancreatic lesions can be observed on T2-weighted images as a low signal and is highly specific to AIP. EUS findings in AIP can be hypoechoic with scattered high-echo spots in the enlarged area in some cases show a diffuse or localized lesion of the parenchyma and irregularities in the main pancreatic duct such as bile duct wall thickening, or produce a duct-penetrating sign[30]. Further use of Positron-Emission-Tomography-Fluorodeoxyglucose can be useful in detecting other organs involved in AIP.

***Artificial intelligence***

The use of artificial intelligence in the medical domain has expanded rapidly in recent years. Artificial intelligence is a mathematical technique that automates the learning and recognition of data patterns. Diagnostic techniques such as digestive EUC (DEUS) can interact with this interface. A database was developed in Rochester using DEUS images of normal pancreas (NP) and pancreas of patients with AIP, PDAC, and CP with the aim to develop a convolutional neural network, a type of network with artificial neurons that recognize and classify images [convolutional neural network (CNN)] able to distinguish between these entities. For every patient in each cohort, all available still images and recorded video assets were identified and extracted. Images and videos obtained from both the radial and curvilinear echoendoscopes were included. Potentially confounding image features and patient identifying information were removed during image processing. Liver images, images with marks or annotations, and images in which calcification was visible were excluded. Using data from the training and validation subsets, various candidate CNN architectures, optimizers, and configurations were implemented, trained, and evaluated to determine an effective design for the EUS-CNN. Occlusion heatmaps were then generated and used to assess the features identified by the CNN model to differentiate all conditions (AIP, PDAC, CP, and NP). In a cohort of 585 patients (146 AIP, 292 PDAC, 72 CP, and 73 NP) with 1174461 extracted images, the CNN was 99% sensitive and 98% specific to differentiate AIP from NP, 95% sensitive and 71% specific to differentiate AIP from CP, 90% sensitive and 93% specific to differentiate AIP from PDAC, and 90% sensitive and 85% specific to differentiate AIP from all other pancreatic diseases[31]. Other groups have used this technology to discriminate portal venous CT images with the aim to differentiate between AIP and PDAC[32].

**Pancreatic cancer as a differential diagnosis**

As the main important differential diagnosis of AIP is pancreatic cancer, it is important to recognize any differences in the clinical, radiological, and histological features[3,6]. Clinically, AIP patients present with mild abdominal pain such as discomfort, rarely with weight loss, and fluctuant jaundice that tends to respond positively to steroid therapy. On the other hand, PDAC patients present severe, persistent, and progressive abdominal pain with weight loss and progressive jaundice. Extrapancreatic manifestations are more frequent in AIP, whereas PDAC is more localized in the pancreatic gland and induces lower bile duct stenosis, presenting metastatic lesions and direct invasion in some cases. Biologically, IgG4 is elevated in AIP patients, although elevated levels have also been reported in a few cases of PDAC[33]. By contrast, elevated carbohydrate antigen 19-9 is rarely seen in AIP. Radiologically, smooth margins and capsule-like rims in the body and tail region that represent severe fibrotic changes are seen in the CT and MRI of patients with AIP. Amelioration of swelling after steroid treatment is a characteristic of AIP, whereas PDAC patients do not or rarely present an improvement. Duct dilatation should raise the suspicion of PDAC. Using contrast-enhanced CT, AIP is characterized by homogenous delayed enhancement of the gland that indicates the diffuse loss of parenchymal volume and severe fibrosis, whereas heterogenous enhancement that represents necrosis or bleeding in the tumor can be seen in PDAC. Using EUS, AIP is characterized by a duct penetrating sign as well as a diffuse homogenous hypoechoic pattern and linear or reticular hyperechoic inclusions that reflect interlobular fibrosis. In PDAC, EUS findings show a localized hypoechoic mass and a double duct sign, often accompanied by lymph node swelling or vascular invasion. Histological patterns of AIP are characterized by periductal lymphoplasmacytic infiltration, storiform fibrosis, and obstructive phlebitis. Immunohistological identification of carcinoma cells is observed in PDAC, and inflammatory reactions can be commonly observed.

**TREATMENT**

Approximately 10%-25% of patients spontaneously improve and do not require specific treatment or intervention. Since no triggers for AIP have been identified to date, no lifestyle modifications have been proposed. Nevertheless, according to the 2017 recommendations, untreated patients with active AIP should receive treatment with the exception of those with a steroid contraindication[34]. The treatment of choice and the standard treatment at present is corticosteroid therapy. There are currently no standard therapeutic protocols regarding the indications for corticosteroid therapy, its duration, posology, monitoring measures, and maintenance therapy. In Asia, the initial dose of prescribed oral prednisone is 0.6 mg/kg/d for 2 to 4 wk, followed by a single maintenance dose of 7.5 mg/d for 6 mo to 3 years. In the United States and Europe, the dose is 40 mg/d for 4 wk followed by a recommended reduction of 5 mg per week following symptom improvement; a single maintenance dose of 5-7.5 mg/d is recommended for 12 wk to 6 mo. A smaller dose of 30 mg/d can be given to diabetic patients[35]. An alternative administration with two courses of methylprednisolone 500 mg for 3 d with a 4-d interval can be useful to induce remission in refractory cases[34].

The aim of treatment is to improve symptoms, prevent fibrosis development within the affected organs, and improve endocrine and exocrine pancreatic insufficiency. Corticosteroid therapy has an effectiveness of around 90%, with a recurrence rate of 30%-50% after reducing treatment. The rate of recurrence is higher in AIP-1 (31%-37.5%) than in AIP-2 (9%-15.9%)[36,37]. Treatment evaluation by imaging and biological analysis is recommended within 1-2 wk of induction.

Three treatment options exist in the case of recurrence. The first approach is to maintain long-term low-dose corticosteroids (7.5 mg/d for 1-3 years), while the second is to use immunomodulator therapy such as azathioprine (2 mg/kg/d for 1-3 years)[38], methotrexate, or mycophenolate mofetil. A new therapeutic approach was proposed with rituximab, a monoclonal anti-CD20 antibody, and it seems to be a promising treatment, notably in IgG4-related disease[34,39].

Diverse studies comparing immunomodulators with corticosteroids alone did not show its superiority in terms of efficacy[34,40]. For patients who are resistant or intolerant of steroids and immunomodulators, rituximab is the only possible therapeutic alternative to induce remission. Rituximab can be used as first-line treatment for patients with a high risk of recurrence. Proximal duct involvement, young age, and higher alkaline phosphatase at initial presentation are high risk factors of recurrence after first-line treatment[41]. Moreover, for these patients with a significantly higher chance of recurrence, an induction and maintenance phase (375 mg/m2 1x/wk every 2-3 mo for 2 years) would be significantly more effective than an induction phase alone (375 mg/m2 per week for 4 wk or two injections of 1000 mg at 15 d interval)[41].

**CONCLUSION**

To conclude, the diagnosis of AIP remains challenging for clinicians as it must rapidly be distinguished from PDAC. The available diagnostic tools such as EUC are currently evolving, and the use of artificial intelligence could lead to the development of new approaches, allowing for a more precise diagnosis of AIP and a better differentiation of the disease from pancreatic cancer. The use of rituximab in the treatment algorithm in case of recurrence has already been proven, and it should be proposed as first-line treatment for patients with risk factors for recurrence. The optimal dose and treatment duration are yet to be defined.

**REFERENCES**

1 **Notohara K**, Burgart LJ, Yadav D, Chari S, Smyrk TC. Idiopathic chronic pancreatitis with periductal lymphoplasmacytic infiltration: clinicopathologic features of 35 cases. *Am J Surg Pathol* 2003; **27**: 1119-1127 [PMID: 12883244 DOI: 10.1097/00000478-200308000-00009]

2 **Zamboni G**, Lüttges J, Capelli P, Frulloni L, Cavallini G, Pederzoli P, Leins A, Longnecker D, Klöppel G. Histopathological features of diagnostic and clinical relevance in autoimmune pancreatitis: a study on 53 resection specimens and 9 biopsy specimens. *Virchows Arch* 2004; **445**: 552-563 [PMID: 15517359 DOI: 10.1007/s00428-004-1140-z]

3 **Chari ST**, Takahashi N, Levy MJ, Smyrk TC, Clain JE, Pearson RK, Petersen BT, Topazian MA, Vege SS. A diagnostic strategy to distinguish autoimmune pancreatitis from pancreatic cancer. *Clin Gastroenterol Hepatol* 2009; **7**: 1097-1103 [PMID: 19410017 DOI: 10.1016/j.cgh.2009.04.020]

4 **Kamisawa T**, Egawa N, Nakajima H, Tsuruta K, Okamoto A. Morphological changes after steroid therapy in autoimmune pancreatitis. *Scand J Gastroenterol* 2004; **39**: 1154-1158 [PMID: 15545176 DOI: 10.1080/00365520410008033]

5 **Yoshida K**, Toki F, Takeuchi T, Watanabe S, Shiratori K, Hayashi N. Chronic pancreatitis caused by an autoimmune abnormality. Proposal of the concept of autoimmune pancreatitis. *Dig Dis Sci* 1995; **40**: 1561-1568 [PMID: 7628283 DOI: 10.1007/BF02285209]

6 **Kamisawa T**, Chari ST, Giday SA, Kim MH, Chung JB, Lee KT, Werner J, Bergmann F, Lerch MM, Mayerle J, Pickartz T, Lohr M, Schneider A, Frulloni L, Webster GJ, Reddy DN, Liao WC, Wang HP, Okazaki K, Shimosegawa T, Kloeppel G, Go VL. Clinical profile of autoimmune pancreatitis and its histological subtypes: an international multicenter survey. *Pancreas* 2011; **40**: 809-814 [PMID: 21747310 DOI: 10.1097/MPA.0b013e3182258a15]

7 **Masamune A**, Kikuta K, Hamada S, Tsuji I, Takeyama Y, Shimosegawa T, Okazaki K; Collaborators. Nationwide epidemiological survey of autoimmune pancreatitis in Japan in 2016. *J Gastroenterol* 2020; **55**: 462-470 [PMID: 31872350 DOI: 10.1007/s00535-019-01658-7]

8 **Schneider A**, Michaely H, Weiss C, Hirth M, Rückert F, Wilhelm TJ, Schönberg S, Marx A, Singer MV, Löhr JM, Ebert MP, Pfützer RH. Prevalence and Incidence of Autoimmune Pancreatitis in the Population Living in the Southwest of Germany. *Digestion* 2017; **96**: 187-198 [PMID: 28957814 DOI: 10.1159/000479316]

9 **Vonlaufen A**, Spahr L, Apte MV, Frossard JL. Alcoholic pancreatitis: A tale of spirits and bacteria. *World J Gastrointest Pathophysiol* 2014; **5**: 82-90 [PMID: 24891979 DOI: 10.4291/wjgp.v5.i2.82]

10 **Shimosegawa T**, Chari ST, Frulloni L, Kamisawa T, Kawa S, Mino-Kenudson M, Kim MH, Klöppel G, Lerch MM, Löhr M, Notohara K, Okazaki K, Schneider A, Zhang L; International Association of Pancreatology. International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology. *Pancreas* 2011; **40**: 352-358 [PMID: 21412117 DOI: 10.1097/MPA.0b013e3182142fd2]

11 **Stone JH**, Khosroshahi A, Deshpande V, Chan JK, Heathcote JG, Aalberse R, Azumi A, Bloch DB, Brugge WR, Carruthers MN, Cheuk W, Cornell L, Castillo CF, Ferry JA, Forcione D, Klöppel G, Hamilos DL, Kamisawa T, Kasashima S, Kawa S, Kawano M, Masaki Y, Notohara K, Okazaki K, Ryu JK, Saeki T, Sahani D, Sato Y, Smyrk T, Stone JR, Takahira M, Umehara H, Webster G, Yamamoto M, Yi E, Yoshino T, Zamboni G, Zen Y, Chari S. Recommendations for the nomenclature of IgG4-related disease and its individual organ system manifestations. *Arthritis Rheum* 2012; **64**: 3061-3067 [PMID: 22736240 DOI: 10.1002/art.34593]

12 **Ghassem-Zadeh S**, Gaida MM, Szanyi S, Acha-Orbea H, Frossard JL, Hinz U, Hackert T, Strobel O, Felix K. Distinct pathophysiological cytokine profiles for discrimination between autoimmune pancreatitis, chronic pancreatitis, and pancreatic ductal adenocarcinoma. *J Transl Med* 2017; **15**: 126 [PMID: 28578701 DOI: 10.1186/s12967-017-1227-3]

13 **Lorenzo D**, Maire F, Stefanescu C, Gornet JM, Seksik P, Serrero M, Bournet B, Marteau P, Amiot A, Laharie D, Trang C, Coffin B, Bellaiche G, Cadiot G, Reenaers C, Racine A, Viennot S, Pauwels A, Bouguen G, Savoye G, Pelletier AL, Pineton de Chambrun G, Lahmek P, Nahon S, Abitbol V; GETAID-AIP study group. Features of Autoimmune Pancreatitis Associated With Inflammatory Bowel Diseases. *Clin Gastroenterol Hepatol* 2018; **16**: 59-67 [PMID: 28782667 DOI: 10.1016/j.cgh.2017.07.033]

14 **Okazaki K**, Kawa S, Kamisawa T, Naruse S, Tanaka S, Nishimori I, Ohara H, Ito T, Kiriyama S, Inui K, Shimosegawa T, Koizumi M, Suda K, Shiratori K, Yamaguchi K, Yamaguchi T, Sugiyama M, Otsuki M; Research Committee of Intractable Diseases of the Pancreas. Clinical diagnostic criteria of autoimmune pancreatitis: revised proposal. *J Gastroenterol* 2006; **41**: 626-631 [PMID: 16932998 DOI: 10.1007/s00535-006-1868-0]

15 **Chari ST**, Smyrk TC, Levy MJ, Topazian MD, Takahashi N, Zhang L, Clain JE, Pearson RK, Petersen BT, Vege SS, Farnell MB. Diagnosis of autoimmune pancreatitis: the Mayo Clinic experience. *Clin Gastroenterol Hepatol* 2006; **4**: 1010-6; quiz 934 [PMID: 16843735 DOI: 10.1016/j.cgh.2006.05.017]

16 **Shimosegawa T**; Working Group Members of the Japan Pancreas Society; Research Committee for Intractable Pancreatic Disease by the Ministry of Labor, Health and Welfare of Japan. The amendment of the Clinical Diagnostic Criteria in Japan (JPS2011) in response to the proposal of the International Consensus of Diagnostic Criteria (ICDC) for autoimmune pancreatitis. *Pancreas* 2012; **41**: 1341-1342 [PMID: 23086247 DOI: 10.1097/MPA.0b013e3182706ed5]

17 **Kawa S**, Kamisawa T, Notohara K, Fujinaga Y, Inoue D, Koyama T, Okazaki K. Japanese Clinical Diagnostic Criteria for Autoimmune Pancreatitis, 2018: Revision of Japanese Clinical Diagnostic Criteria for Autoimmune Pancreatitis, 2011. *Pancreas* 2020; **49**: e13-e14 [PMID: 31856100 DOI: 10.1097/MPA.0000000000001443]

18 **de Pretis N**, Frulloni L. Autoimmune pancreatitis type 2. *Curr Opin Gastroenterol* 2020; **36**: 417-420 [PMID: 32618613 DOI: 10.1097/MOG.0000000000000655]

19 **Hart PA**, Zen Y, Chari ST. Recent Advances in Autoimmune Pancreatitis. *Gastroenterology* 2015; **149**: 39-51 [PMID: 25770706 DOI: 10.1053/j.gastro.2015.03.010]

20 **Noguchi K**, Nakai Y, Mizuno S, Hirano K, Kanai S, Suzuki Y, Inokuma A, Sato T, Hakuta R, Ishigaki K, Saito K, Saito T, Hamada T, Takahara N, Kogure H, Isayama H, Koike K. Role of Endoscopic Ultrasonography-Guided Fine Needle Aspiration/Biopsy in the Diagnosis of Autoimmune Pancreatitis. *Diagnostics (Basel)* 2020; **10** [PMID: 33203118 DOI: 10.3390/diagnostics10110954]

21 **Yoon SB**, Moon SH, Song TJ, Kim JH, Kim MH. Endoscopic ultrasound-guided fine needle aspiration versus biopsy for diagnosis of autoimmune pancreatitis: Systematic review and comparative meta-analysis. *Dig Endosc* 2021; **33**: 1024-1033 [PMID: 33030283 DOI: 10.1111/den.13866]

22 **Iwashita T**, Yasuda I, Doi S, Ando N, Nakashima M, Adachi S, Hirose Y, Mukai T, Iwata K, Tomita E, Itoi T, Moriwaki H. Use of samples from endoscopic ultrasound-guided 19-gauge fine-needle aspiration in diagnosis of autoimmune pancreatitis. *Clin Gastroenterol Hepatol* 2012; **10**: 316-322 [PMID: 22019795 DOI: 10.1016/j.cgh.2011.09.032]

23 **Deheragoda MG**, Church NI, Rodriguez-Justo M, Munson P, Sandanayake N, Seward EW, Miller K, Novelli M, Hatfield AR, Pereira SP, Webster GJ. The use of immunoglobulin g4 immunostaining in diagnosing pancreatic and extrapancreatic involvement in autoimmune pancreatitis. *Clin Gastroenterol Hepatol* 2007; **5**: 1229-1234 [PMID: 17702660 DOI: 10.1016/j.cgh.2007.04.023]

24 **Tsang KFP**, Oppong WK, Leeds SJ, Bekkali LHN, Nayar KM. Does IgG4 level at the time of diagnosis correlate with disease outcome in IgG4-Related disease? *Pancreatology* 2019; **19**: 177-181 [PMID: 30509569 DOI: 10.1016/j.pan.2018.10.013]

25 **Hart PA**, Smyrk TC, Chari ST. Lymphoplasmacytic sclerosing pancreatitis without IgG4 tissue infiltration or serum IgG4 elevation: IgG4-related disease without IgG4. *Mod Pathol* 2015; **28**: 238-247 [PMID: 25081756 DOI: 10.1038/modpathol.2014.91]

26 **Soliman H**, Vullierme MP, Maire F, Hentic O, Ruszniewski P, Lévy P, Rebours V. Risk factors and treatment of relapses in autoimmune pancreatitis: Rituximab is safe and effective. *United European Gastroenterol J* 2019; **7**: 1073-1083 [PMID: 31662864 DOI: 10.1177/2050640619862459]

27 **Khosroshahi A**, Carruthers MN, Deshpande V, Unizony S, Bloch DB, Stone JH. Rituximab for the treatment of IgG4-related disease: lessons from 10 consecutive patients. *Medicine (Baltimore)* 2012; **91**: 57-66 [PMID: 22210556 DOI: 10.1097/MD.0b013e3182431ef6]

28 **Wallace ZS**, Mattoo H, Carruthers M, Mahajan VS, Della Torre E, Lee H, Kulikova M, Deshpande V, Pillai S, Stone JH. Plasmablasts as a biomarker for IgG4-related disease, independent of serum IgG4 concentrations. *Ann Rheum Dis* 2015; **74**: 190-195 [PMID: 24817416 DOI: 10.1136/annrheumdis-2014-205233]

29 **Majumder S**, Takahashi N, Chari ST. Autoimmune Pancreatitis. *Dig Dis Sci* 2017; **62**: 1762-1769 [PMID: 28365915 DOI: 10.1007/s10620-017-4541-y]

30 **Farrell JJ**, Garber J, Sahani D, Brugge WR. EUS findings in patients with autoimmune pancreatitis. *Gastrointest Endosc* 2004; **60**: 927-936 [PMID: 15605008 DOI: 10.1016/s0016-5107(04)02230-8]

31 **Marya NB**, Powers PD, Chari ST, Gleeson FC, Leggett CL, Abu Dayyeh BK, Chandrasekhara V, Iyer PG, Majumder S, Pearson RK, Petersen BT, Rajan E, Sawas T, Storm AC, Vege SS, Chen S, Long Z, Hough DM, Mara K, Levy MJ. Utilisation of artificial intelligence for the development of an EUS-convolutional neural network model trained to enhance the diagnosis of autoimmune pancreatitis. *Gut* 2021; **70**: 1335-1344 [PMID: 33028668 DOI: 10.1136/gutjnl-2020-322821]

32 **Ziegelmayer S**, Kaissis G, Harder F, Jungmann F, Müller T, Makowski M, Braren R. Deep Convolutional Neural Network-Assisted Feature Extraction for Diagnostic Discrimination and Feature Visualization in Pancreatic Ductal Adenocarcinoma (PDAC) versus Autoimmune Pancreatitis (AIP). *J Clin Med* 2020; **9** [PMID: 33322559 DOI: 10.3390/jcm9124013]

33 **Ghazale A**, Chari ST, Smyrk TC, Levy MJ, Topazian MD, Takahashi N, Clain JE, Pearson RK, Pelaez-Luna M, Petersen BT, Vege SS, Farnell MB. Value of serum IgG4 in the diagnosis of autoimmune pancreatitis and in distinguishing it from pancreatic cancer. *Am J Gastroenterol* 2007; **102**: 1646-1653 [PMID: 17555461 DOI: 10.1111/j.1572-0241.2007.01264.x]

34 **Okazaki K**, Chari ST, Frulloni L, Lerch MM, Kamisawa T, Kawa S, Kim MH, Lévy P, Masamune A, Webster G, Shimosegawa T. International consensus for the treatment of autoimmune pancreatitis. *Pancreatology* 2017; **17**: 1-6 [PMID: 28027896 DOI: 10.1016/j.pan.2016.12.003]

35 **Nagpal SJS**, Sharma A, Chari ST. Autoimmune Pancreatitis. *Am J Gastroenterol* 2018; **113**: 1301 [PMID: 29910463 DOI: 10.1038/s41395-018-0146-0]

36 **Hart PA**, Kamisawa T, Brugge WR, Chung JB, Culver EL, Czakó L, Frulloni L, Go VL, Gress TM, Kim MH, Kawa S, Lee KT, Lerch MM, Liao WC, Löhr M, Okazaki K, Ryu JK, Schleinitz N, Shimizu K, Shimosegawa T, Soetikno R, Webster G, Yadav D, Zen Y, Chari ST. Long-term outcomes of autoimmune pancreatitis: a multicentre, international analysis. *Gut* 2013; **62**: 1771-1776 [PMID: 23232048 DOI: 10.1136/gutjnl-2012-303617]

37 **Tacelli M**, Celsa C, Magro B, Barresi L, Guastella S, Capurso G, Frulloni L, Cabibbo G, Cammà C. Risk Factors for Rate of Relapse and Effects of Steroid Maintenance Therapy in Patients With Autoimmune Pancreatitis: Systematic Review and Meta-analysis. *Clin Gastroenterol Hepatol* 2019; **17**: 1061-1072.e8 [PMID: 30312787 DOI: 10.1016/j.cgh.2018.09.051]

38 **de Pretis N**, Amodio A, Bernardoni L, Campagnola P, Capuano F, Chari ST, Crinò S, Gabbrielli A, Massella A, Topazian M, Frulloni L. Azathioprine Maintenance Therapy to Prevent Relapses in Autoimmune Pancreatitis. *Clin Transl Gastroenterol* 2017; **8**: e90 [PMID: 28448071 DOI: 10.1038/ctg.2017.17]

39 **Sandanayake NS**, Church NI, Chapman MH, Johnson GJ, Dhar DK, Amin Z, Deheragoda MG, Novelli M, Winstanley A, Rodriguez-Justo M, Hatfield AR, Pereira SP, Webster GJ. Presentation and management of post-treatment relapse in autoimmune pancreatitis/immunoglobulin G4-associated cholangitis. *Clin Gastroenterol Hepatol* 2009; **7**: 1089-1096 [PMID: 19345283 DOI: 10.1016/j.cgh.2009.03.021]

40 **Hart PA**, Topazian MD, Witzig TE, Clain JE, Gleeson FC, Klebig RR, Levy MJ, Pearson RK, Petersen BT, Smyrk TC, Sugumar A, Takahashi N, Vege SS, Chari ST. Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience. *Gut* 2013; **62**: 1607-1615 [PMID: 22936672 DOI: 10.1136/gutjnl-2012-302886]

41 **Majumder S**, Mohapatra S, Lennon RJ, Piovezani Ramos G, Postier N, Gleeson FC, Levy MJ, Pearson RK, Petersen BT, Vege SS, Chari ST, Topazian MD, Witzig TE. Rituximab Maintenance Therapy Reduces Rate of Relapse of Pancreaticobiliary Immunoglobulin G4-related Disease. *Clin Gastroenterol Hepatol* 2018; **16**: 1947-1953 [PMID: 29526692 DOI: 10.1016/j.cgh.2018.02.049]

**Footnotes**

**Conflict-of-interest statement:** All the authors report having no relevant conflicts of interest for this article.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed

**Peer-review model:** Single blind

**Peer-review started:** August 18, 2022

**First decision:** September 8, 2022

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** Switzerland

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C, C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Morya AK, India; Spadaccini M, Italy **S-Editor:** Wang JJ **L-Editor:** Filipodia **P-Editor:**

**Table 1 Characteristics of the two subtypes of autoimmune pancreatitis**

|  |  |  |
| --- | --- | --- |
| **Characteristic** | **AIP-1** | **AIP-2** |
| Male/female ratio | 3/1 | 1/1 |
| Mean age | 65 yr | 40 yr  |
| Geographical distribution | Asia > Europe and United States | Europe and United States > Asia |
| Clinical presentation | Jaundice 60%-80%. Acute pancreatitis 15%. Weight loss 65% | Acute pancreatitis 80%. Jaundice < 30% |
| Biological presentation | IgG4 > 1.35 g/L (sensitivity 70%, specificity 93%). IgG4 > 2.7 g/L (sensitivity 53%, specificity 99%). Lipase < 3xN. Cholestasis: > 80% of cases. Diabetes: 65% of cases. Insulin-dependent diabetes: 20% of cases. Exocrine pancreatic insufficiency: 40% of cases | Unspecific. Lipase > 3xN. Rare endocrine and exocrine pancreatic insufficiency |
| Histological criteria | Lymphoplasmacytic infiltration without neutrophils. Storiform fibrosis. Obliterative venulitis. IgG4 plasma cells > 10 in a high-power field | Destruction of inter- and intralobular ducts by neutrophils (granulocytic epithelial lesions). Few or no IgG4 plasma cells |
| Relapse rate after corticosteroid therapy | > 30% | < 15% |

AIP: Autoimmune pancreatitis; IgG: Immunoglobulin G.

**Table 2 Summary table of the** **International Consensus Diagnostic Criteria for autoimmune pancreatitis-1[10]**

|  |  |  |
| --- | --- | --- |
| **ICDC** | **Level 1** | **Level 2**  |
| P: Parenchymal imaging | Typical: Diffuse enlargement with delayed enhancement (rim-like enhancement) | Indeterminate: Segmental or focal enlargement with delayed enhancement |
| D: Ductal imaging | Single long stricture (> 1/3 length of MPD) or multiple stricture without marked upstream dilatation | Segmental or focal narrowing without marked upstream dilatation (< 5 mm) |
| S: Serology | IgG4 > 2x upper limit of normal value (> 2.70 g/L) | IgG4 rate: 1-2x upper limit of normal value |
| OOI: Other organ involvement | Histology of extra-pancreatic organ (3/4) | Histology of extra-pancreatic organ must show both: (1) Periductal lympho-plasmacytic infiltration without granulocyte epithelial lesions; and (2) > 10 cells/HPF of IgG4 positive cells |
| Typical radiological evidence: (1) Stenosis of intrahepatic bile duct or proximal and distal common bile duct; and (2) Retroperitoneal fibrosis | Physical or radiological evidence (1/2): (1) Symmetrically enlarged salivary/lachrymal glands; and (2) Radiological renal involvement |
| H: Pancreatic histology | 3/4 criteria | 2/4 criteria |
| Periductal lymphoplasmacytic infiltration without granulocyte epithelial lesions |
| Obliterative phlebitis |
| Storiform fibrosis |
| > 10 cells/HPF of IgG4 positive cells |
| Rt: Corticosteroid response | Rapid (≤ 2 wk) radiologically demonstrable resolution or marked improvement in pancreatic/extrapancreatic manifestation |

HPF: High power field; ICDC: International Consensus Diagnostic Criteria; IgG: Immunoglobulin G; MPD: Main pancreatic duct.

**Table 3 Summary table of the International Consensus Diagnostic Criteria for autoimmune pancreatitis-2[10]**

|  |  |  |
| --- | --- | --- |
| **ICDC** | **Level 1** | **Level 2**  |
| P: Parenchymal imaging | Typical: Diffuse enlargement with delayed enhancement (rim-like enhancement) | Indeterminate: Segmental or focal enlargement with delayed enhancement |
| D: Ductal imaging | Single long stricture (> 1/3 length of MPD) or multiple stricture without marked upstream dilatation | Segmental or focal narrowing without marked upstream dilatation (< 5 mm) |
| OOI: Other organ involvement |  | Clinically diagnosed inflammatory bowel disease |
| H: Pancreatic histology | Both of the following: (1) Granulocytic infiltration of duct wall with or without granulocytic acinar inflammation; and (2) Absent or scant (0-10 cells/HPF) IgG4-positive cells  | Both of the following: (1) Granulocytic and lymphoplasmacytic acinar infiltration; and (2) Absent or scant (0-10 cells/HPF) IgG4-positive cells |
| Rt: Corticosteroid response | Rapid (≤ 2 wk) radiologically demonstrable resolution or marked improvement in manifestations |

HPF: High power field; ICDC: International Consensus Diagnostic Criteria; IgG: Immunoglobulin G; MPD: Main pancreatic duct.